https://european-biotechnology.com/wp-content/uploads/2024/07/Draupnir-Bio-.png11681746Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2024-07-17 11:15:572024-07-22 11:31:00Draupnir Bio ApS raises further equity
CordenPharma is making a record investment of about €900m over the next three years in expanding its peptide platform, both at its Colorado, US site and in Europe.
In the largest expansion in the company’s 150-year history, the Laupheim-headquartered CDMO Rentschler Biopharma SE has launched a new production line at its site in Milford, USA.
German iRhom2-targeted antibody specialist SciRhom GmbH has closed an oversubscribed €63m Series A financing that will be used to provide clinical proof of concept in autoimmune disorders.
https://european-biotechnology.com/wp-content/uploads/2024/07/EuroscreenFast_s_headquarters.jpeg168300Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2024-07-09 08:51:002024-07-16 18:29:28EuroscreenFast and GW Vitek announce distribution partnership in Korea
The European Commission has fully upheld the complaint by PharmaMar SA due to conflicts of interest of leading EMA experts in the (non-)authorisation of Aplidin.
https://european-biotechnology.com/wp-content/uploads/2024/07/Bildschirmfoto_2024-07-09_um_09.31.12.png634956Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2024-07-09 07:34:442024-07-16 18:30:54EMA-Gate: PharmaMar wins suit against EMA
Danish Novo Holdings A/S and Abingworth co-led the largest European Series A financing round this year. Together with existing and new investors, they put £90m into cancer ADC specialist Myricx Bio Ltd.
https://european-biotechnology.com/wp-content/uploads/2024/07/Myricx_Bio3.png266522Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2024-07-08 09:31:082024-07-16 18:33:03Novo Holdings and Abingworth co-lead £90m financing in Myricx Bio Ltd
Draupnir Bio ApS raises further equity
Latest NewsTargeted protein degradation Draupnir Bio Aps has raised further €12m in an equitiy investment to advance its preclinical pipeline.
CordenPharma invests €900m in peptide patform expansion
Latest NewsCordenPharma is making a record investment of about €900m over the next three years in expanding its peptide platform, both at its Colorado, US site and in Europe.
Catalym raises US$150m
Latest NewsGerman cancer specialist Catalym GmbH has raised US$150m to finance proof-of-concept studies.
Sensorion achieves milestones in Phase II trial
Latest NewsFrench Sensorion SA has reported new efficacy endpoints data from SENS-401 in a Phase II study for the preservation of residual hearing loss.
Rentschler doubles cGMP capacity
Latest NewsIn the largest expansion in the company’s 150-year history, the Laupheim-headquartered CDMO Rentschler Biopharma SE has launched a new production line at its site in Milford, USA.
SciRhom GmbH closes €63m Series A financing
Latest NewsGerman iRhom2-targeted antibody specialist SciRhom GmbH has closed an oversubscribed €63m Series A financing that will be used to provide clinical proof of concept in autoimmune disorders.
Ligand Pharma to acquire Apeiron Biologics
Latest NewsAustrian Apeiron Biologics goes to Ligand Pharmaceuticals for US$100m.
EuroscreenFast and GW Vitek announce distribution partnership in Korea
Latest NewsBelgium-headquarted GCPR-screening specialist EuroscreenFast and Asian distributor GW Vitek have inked a strategic collaboration.
EMA-Gate: PharmaMar wins suit against EMA
Latest NewsThe European Commission has fully upheld the complaint by PharmaMar SA due to conflicts of interest of leading EMA experts in the (non-)authorisation of Aplidin.
Novo Holdings and Abingworth co-lead £90m financing in Myricx Bio Ltd
Latest NewsDanish Novo Holdings A/S and Abingworth co-led the largest European Series A financing round this year. Together with existing and new investors, they put £90m into cancer ADC specialist Myricx Bio Ltd.